Currently, both TPS and CPS scoring systems specifically avoid including PD-L1 expression on vasculature, yet PD-L1 is highly expressed on both human and murine lymphatic endothelial cells and may inhibit anti-tumor immunity [161,162]). Here, CD274 is linked to neoplasm.